Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Beuzeboc

Showing results (61-70 of 128) with videos related to

Pageof 13
Sort By:
Cancer|July 20, 2007
Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) studyVincent Launay-Vacher, Stéphane Oudard, Nicolas Janus, et al.
Cancer|May 10, 2002
HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic processAnne Vincent-Salomon, Michel Jouve, Pascal Genin, et al.
Anti-Cancer Drugs|September 16, 2005
Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbiditiesOlivier Mir, Jérôme Alexandre, Stanislas Ropert, et al.
Cancer Treatment Reviews|September 25, 2010
Cardiac toxicity in breast cancer patients: from a fractional point of view to a global assessmentCyrus Chargari, Krassen M Kirov, Marc A Bollet, et al.
BJU International|September 16, 2010
Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trialNicholas D James, Armelle Caty, Heather Payne, et al.
European Urology|August 19, 2008
Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancerAntoine Italiano, Cécile Ortholan, Stéphane Oudard, et al.
Drug Design, Development and Therapy|September 19, 2017
Radium 223 dichloride for prostate cancer treatmentEmmanuel Deshayes, Mathieu Roumiguie, Constance Thibault, et al.
Critical Reviews in Oncology/Hematology|November 8, 2008
Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA studyVincent Launay-Vacher, Jean-Philippe Spano, Nicolas Janus, et al.
Breast Cancer Research : BCR|February 15, 2012
Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational studyFrançois-Clément Bidard, David Hajage, Thomas Bachelot, et al.
American Journal of Clinical Oncology|March 2, 2011
Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancerChristophe Le Tourneau, Sarah Dettwiler, Philippe Beuzeboc, et al.
Pageof 13

Showing results (61-70 of 128) with videos related to

Sort By:
Pageof 13
Cancer|July 20, 2007
Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) studyVincent Launay-Vacher, Stéphane Oudard, Nicolas Janus, et al.
Cancer|May 10, 2002
HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic processAnne Vincent-Salomon, Michel Jouve, Pascal Genin, et al.
Anti-Cancer Drugs|September 16, 2005
Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbiditiesOlivier Mir, Jérôme Alexandre, Stanislas Ropert, et al.
Cancer Treatment Reviews|September 25, 2010
Cardiac toxicity in breast cancer patients: from a fractional point of view to a global assessmentCyrus Chargari, Krassen M Kirov, Marc A Bollet, et al.
BJU International|September 16, 2010
Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trialNicholas D James, Armelle Caty, Heather Payne, et al.
European Urology|August 19, 2008
Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancerAntoine Italiano, Cécile Ortholan, Stéphane Oudard, et al.
Drug Design, Development and Therapy|September 19, 2017
Radium 223 dichloride for prostate cancer treatmentEmmanuel Deshayes, Mathieu Roumiguie, Constance Thibault, et al.
Critical Reviews in Oncology/Hematology|November 8, 2008
Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA studyVincent Launay-Vacher, Jean-Philippe Spano, Nicolas Janus, et al.
Breast Cancer Research : BCR|February 15, 2012
Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational studyFrançois-Clément Bidard, David Hajage, Thomas Bachelot, et al.
American Journal of Clinical Oncology|March 2, 2011
Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancerChristophe Le Tourneau, Sarah Dettwiler, Philippe Beuzeboc, et al.
Pageof 13